RÉSUMÉ
Posttransplant erythrocytosis (PTE) is a common complication of renal transplantation, which can occur in approximately 10% to 15% of renal transplant patients and usually affects males with relatively good renal function. It is also associated with an increased incidence of thromboembolic events. Clinical manifestations of PTE include malaise, headache, plethora, lethargy, and dizziness. It is correlated with use of cyclosporin, gender, posttransplant renal function, and type of antihypertensive medication. The angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor is preferred as an initial treatment for PTE because these agents are effective and reasonably safe in the majority of patients with PTE, and can also provide a necessary antihypertensive effect for kidney transplant patients. We report here on a 35-year-old male who had erythrocytosis after renal transplantation. After renal transplantation, his level of hemoglobin was 21 g/dL. We treated this patient with ARB and his symptoms and signs have been completely relieved.
Sujet(s)
Adulte , Humains , Mâle , Antagonistes des récepteurs aux angiotensines , Angiotensines , Ciclosporine , Sensation vertigineuse , Céphalée , Incidence , Transplantation rénale , Rein , Léthargie , PolyglobulieRÉSUMÉ
No abstract available.
Sujet(s)
Humains , Mâle , Maladies asymptomatiques , Marqueurs biologiques/analyse , Biopsie , Cristallisation , Technique d'immunofluorescence , Chaines légères des immunoglobulines/analyse , Maladies du rein/diagnostic , Tubules contournés proximaux/immunologie , Microscopie électronique , Protéinurie/diagnosticRÉSUMÉ
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of diverse autoantibodies with various systemic organ involvements. In patients with SLE, autoantibodies, such as antinuclear antibody (ANA) and anti-dsDNA antibody, play an important role not only in diagnosing the disease, but also representing the pathogenesis of the disease. ANA is the main screening tool in diagnosis and serum complement levels and anti-dsDNA antibody level are closely related to the disease activities. Nevertheless, exceptionally, some patients represent with negative ANA and/or anti-dsDNA antibody leading to difficulties in diagnosing the disease. Here, we report a case of 37-year old female SLE patient with negative ANA, negative anti-dsDNA antibody, and positive anti-Ro/SSA antibody, which manifested with nephrotic syndrome.